Aclaris Therapeutics Inc. (ACRS) Major Shareholder Ventures Fund Vii L.P. Vivo Sells 907,828 Shares
Aclaris Therapeutics Inc. (NASDAQ:ACRS) major shareholder Ventures Fund Vii L.P. Vivo sold 907,828 shares of the stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $23.03, for a total transaction of $20,907,278.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) traded down 2.85% during mid-day trading on Monday, hitting $25.24. 61,003 shares of the stock were exchanged. Aclaris Therapeutics Inc. has a one year low of $14.12 and a one year high of $33.88. The company’s market cap is $540.94 million. The company has a 50-day moving average price of $22.89 and a 200-day moving average price of $21.15.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.16. On average, analysts predict that Aclaris Therapeutics Inc. will post ($2.39) earnings per share for the current fiscal year.
ACRS has been the subject of several recent research reports. Jefferies Group reaffirmed a “buy” rating and issued a $32.00 price objective (up previously from $29.00) on shares of Aclaris Therapeutics in a research report on Friday. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, JMP Securities began coverage on shares of Aclaris Therapeutics in a research report on Friday, September 30th. They set an “outperform” rating and a $34.00 price target for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $32.50.
Several large investors have recently made changes to their positions in ACRS. BlackRock Advisors LLC raised its stake in shares of Aclaris Therapeutics by 58.9% in the third quarter. BlackRock Advisors LLC now owns 4,550 shares of the company’s stock valued at $117,000 after buying an additional 1,686 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Aclaris Therapeutics during the third quarter valued at about $192,000. Strs Ohio raised its stake in shares of Aclaris Therapeutics by 170.0% in the third quarter. Strs Ohio now owns 8,100 shares of the company’s stock valued at $207,000 after buying an additional 5,100 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Aclaris Therapeutics during the third quarter valued at about $210,000. Institutional investors and hedge funds own 72.72% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor.
Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.